TAXUS(R) Liberte(TM) stent system receives European approval for three complex coronary procedures
16 Mai 2006 - 9:39PM
PR Newswire (US)
Boston Scientific's second-generation stent system now approved for
treatment of acute mycocardial infarction, total occlusions and
in-stent restenosis VANCOUVER, May 16 /PRNewswire-FirstCall/ --
Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI; TSX: ANP) today
announced that its corporate partner Boston Scientific Corporation
("BSC") has received indication extensions to the European CE mark
for its TAXUS(R) Liberte(TM) paclitaxel-eluting coronary stent
system for use in some of the most challenging coronary procedures.
The new labeling reflects a review of TAXUS clinical data by the
European regulatory agency. In addition to its existing indication
for the treatment of de-novo lesions in native coronary arteries,
the TAXUS Liberte stent system is now indicated in Europe for the
treatment of restenotic lesions (in-stent restenosis, or ISR) and
total occlusions (TO) in patients with coronary artery disease,
including acute myocardial infarction (AMI). These three new
indications account for more than 20 percent of all coronary
interventions. The TAXUS Liberte stent system is now the only
drug-eluting stent system with these new indications for use in
Europe. This revised labeling follows the excellent clinical
outcomes the TAXUS stent system has shown in the treatment of
complex lesions in recent clinical trials and registries, including
the TAXUS V ISR trial and the MILESTONE II, WISDOM, ARRIVE, and
OLYMPIA registries. In addition to the three new indications, the
large vessel diameter TAXUS Liberte stent also received the CE
mark. This stent uses a modified cell design intended for drug
delivery in larger vessels, and will be available in a 4.0 mm
diameter and seven different lengths. BSC acquired worldwide
exclusive rights from Angiotech to use paclitaxel to coat its
coronary stent products and has co-exclusive rights to other
vascular and non-vascular products. About Angiotech
Pharmaceuticals, Inc. ------------------------------------- Founded
in 1992, Angiotech Pharmaceuticals, Inc. is a global specialty
pharmaceutical and medical device company, with 14 facilities in 6
countries and over 1,500 dedicated employees, that discovers,
develops and markets innovative, minimally invasive treatment
solutions for diseases or complications associated with medical
device implants, surgical interventions and acute injury. To find
out more about Angiotech Pharmaceuticals, Inc.
(NASDAQ:ANPINASDAQ:TSX:NASDAQ:ANP), please visit our website at
http://www.angiotech.com/. Statements contained in this press
release or in our other written or oral public communications that
are not based on historical or current fact, including without
limitation statements containing the words "believes," "may,"
"plans," "will," "estimate," "continue," "anticipates," "intends,"
"expects" and similar expressions, constitute "forward-looking
statements" within the meaning of the U.S. Private Securities
Litigation Reform Act of 1995 and constitute "forward-looking
information" within the meaning of applicable Canadian securities
laws. All such statements are made pursuant to the "safe harbor"
provisions of applicable securities legislation. Such
forward-looking statements are based on assumptions that involve
known and unknown risks, uncertainties and other factors that may
cause the actual results, events or developments to be materially
different from any future results, events or developments expressed
or implied by such forward-looking statements. Forward-looking
statements in this release include the statements regarding: the
applicability of the clinical data to patient populations and the
accuracy of information concerning the statement that the three new
indications granted to BSC in Europe accounted for more than 20% of
coronary interventions. These statements are subject to risks and
uncertainties that could cause actual results to differ materially
from those projected. These risks and uncertainties include, among
others, the possibility of a change in the regulatory environment
in Europe and the risks and uncertainties described in Angiotech's
filings with the United States Securities and Exchange Commission
or the Canadian securities regulators. The forward looking
statements are also based on a number of assumptions, including the
applicability of the clinical data to patient populations; that the
study results were collected and reported in accordance with the
study protocol; that the study results have been accurately
interpreted; and the accuracy of information concerning the
statement that the three new indications granted to BSC in Europe
account for more than 20% of coronary interventions. Given these
uncertainties, readers are cautioned not to place undue reliance on
such forward-looking statements. The Company does not assume the
obligation to update any forward-looking statements. FOR ADDITIONAL
INFORMATION: --------------------------- Analysts and Investors:
Janet Craig VP, Investor Relations and Corporate Communications
Angiotech Pharmaceuticals, Inc. (604) 221-6933 Media: Jodi Regts
Manager, Corporate Communications Angiotech Pharmaceuticals, Inc.
(604) 221-7930 DATASOURCE: Angiotech Pharmaceuticals, Inc. CONTACT:
Analysts and Investors: Janet Craig, VP, Investor Relations and
Corporate Communications, Angiotech Pharmaceuticals, Inc., (604)
221-6933; Media: Jodi Regts, Manager, Corporate Communications,
Angiotech Pharmaceuticals, Inc., (604) 221-7930
Copyright
Angiotech Pharmaceuticals - Common Shares (MM) (NASDAQ:ANPI)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
Angiotech Pharmaceuticals - Common Shares (MM) (NASDAQ:ANPI)
Historical Stock Chart
Von Jul 2023 bis Jul 2024